QUESTION 1: Should patients with brain metastases receive chemotherapy in addition to whole brain radiotherapy (WBRT) for the treatment of their brain metastases? TARGET POPULATION: This recommendation applies to adult patients with newly diagnosed brain metastases amenable to both chemotherapy and radiation treatment.
B
rain metastases commonly present in patients with systemic malignancy. As systemic treatment has improved, and patients are displaying an increase in overall survival, the incidence of brain metastases has also increased, ranging between 20% and 40%. [1] [2] [3] [4] [5] No definitive trial has established a routine role for chemotherapy for the treatment of brain metastasis, either as stand-alone treatment for brain metastases or in ABBREVIATIONS: SRS, stereotactic radiosurgery; WBRT, whole brain radiation therapy combination. This literature review sought to identify evidence-based guidelines for the use of chemotherapy as a stand-alone treatment for brain metastases or in combination with either WBRT or SRS.
METHODS
Details of the systematic literature review are provided in the full text of this guideline (https://www.cns.org/guidelines/guidelines-treatmentadults-metastatic-brain-tumors/chapter_5) and in the methodology article (https://www.cns.org/guidelinestreatment-adults-metastatic-brain-tumors/chapter_1) of this guidelines series. A comprehensive systematic review of the literature was performed. The following electronic databases were searched from 1990 to December 31, 2015: MEDLINE, Cochrane Database of Systematic Reviews, Cochrane Controlled Trials Registry, and Cochrane Database of Abstracts of Reviews of Effects. Both the quality of the evidence and the strength of the recommendations were graded according to the American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) criteria. These criteria are provided in the methodology paper for this guideline series and can also be found at (https://www.cns.org/ guidelines-treatment-adults-metastatic-brain-tumors/chapter_1).
RESULTS
The literature search resulted in the identification of 3170 citations, of which 3146 were eliminated at abstract review as not having relevance to the specific questions. The remaining 24 studies were subject to full text screening, and 7 were excluded because the data were heavily weighted toward targeted agents and not cytotoxic chemotherapeutics. Seventeen eligible studies [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] were therefore fully reviewed and form the basis for this report (see Tables 1-3 , https://www.cns.org/guidelines/ guidelines-treatment-adults-metastatic-brain-tumors/chapter_5_ table_1, https://www.cns.org/guidelines/guidelines-treatmentadults-metastatic-brain-tumors/chapter_5_table_2, https://www. cns.org/guidelines/guidelines-treatment-adults-metastatic-braintumors/chapter_5_table_3; Figure 1 , https://www.cns.org/ guidelines/guidelines-treatment-adults-metastatic-brain-tumors/ chapter_5_figure_1).
The authors from the eligible studies showed that routine use of chemotherapy following WBRT for brain metastases does not increase survival yielding a level 1 recommendation. On subgroup analysis, resulting in a level 3 recommendation, patients with triple negative tumors displayed increased overall survival and increased progression-free survival for those receiving WBRT plus temozolomide as compared to WBRT alone. Validation of this finding will require future clinical trials.
The authors of the eligible studies revealed that routine use of chemotherapy following SRS does not increase survival and therefore is not recommended (level 1 recommendation). Both the class I and the class II studies displayed no difference in either overall survival or progression-free survival between treatment groups as a whole. The class II study displayed a significant difference with regard to overall and progression-free survival in lung adenocarcinoma patients receiving SRS in combination with chemotherapy as compared to other groups, yielding a level 2 recommendation for that subgroup. This potential benefit of combination treatment requires validation in a randomized phase III trial.
The authors of the eligible studies presented data that routine use of cytotoxic chemotherapy alone for brain metastases does not increase survival leading to a level 1 recommendation against this practice. Both of the class I studies displayed a significantly higher median time to intracranial tumor progression in patients receiving WBRT plus chemotherapy as compared to chemotherapy alone. No difference was noted on tumor response or overall survival. Both of the class II studies displayed no difference in overall survival in patients receiving chemotherapy alone as compared to combination treatments.
DISCUSSION AND CONCLUSION
The use of chemotherapy in the treatment of brain metastases has been explored in a limited number of randomized controlled trials, limiting the utility of the recommendations generated by this review. The available literature failed to display a clear and robust survival benefit with cytotoxic chemotherapeutic agents alone or in combination with WBRT or SRS.
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